analysis

The Boston-based firm reportedly sees ARNA launching its weight-loss drug in about two years, matching company guidance, and becoming profitable in 2015. The Summer Street analysts also expect the company to raise additional capit

Arena Pharma (ARNA) share are off about 2% this morning despite an upgrade for the stock by Summer Street Research Partners, boosting its rating to "neutral" from "sell."

A Global analyst reportedly cites CRR's $4.2-mln purchase yesterday of a 400,000-sq-ft building and adjacent 38.6-acre property in Marshfield, Wis., as a positive development. The company did not disclose its plans for the site, a

The stock slipped 25 cents at the bell to open at $34.67 and hit a low of $34.62 before finding support to add back 61 cents and trade at $35.23, up 31 cents, or 0.89%.

The airbag recall applies to almost 96,000 Cadillac CTS models built between 2005 and 2007.

General Motors Co. (GM) has shed an opening bell loss and is up near 1% despite announcing a recall of about 100,000 vehicles to fix a rear axle problem, which could inadvertently lock, and the passenger-side airbag, which is susc

UBS analyst David Deckelbaum maintained his neutral rating on Forest Oil (NYSE:FST) and raised his price target to $39 from $31.
The bank sees 2010 EPS of $5.23 and sees 2011 EPS of $5.44.
Forest Oil is currently above

MDP will replace Cincinnati Bell (CBB) in the S&P MidCap 400 index, and CBB will replace Penford (PENX) in the S&P SmallCap 600 index.

Cincinnati Bell is trading at $2.35, down 3 cents or 1.26%.

MMI is being spun off from Motorola, but the deal isn't expected to take place until January and the stock is not trading yet.

Penford is trading at $6.25, down 77 cents, or 10.97%.

Meredith (MDP) dips after Standard & Poor's says MDP will be replaced by soon-to-be-public Motorola Mobility Holdings (MMI) in the S&P 500 index.

Citigroup Inc. lifted its price target by $2.00 for Walgreen Co.

The rate is above October's downwardly revised rate of 275,000.

The rate of sales last month was 21.2% under the sales rate in November 2009.

For new houses sold in November, the median sales price rose 8% from October to $213,000.

However, when compared to the prior year, median sales prices last month declined 2.6%.

The Commerce Department reported Wednesday that single-family home sales rose 5.5% during November to a seasonally adjusted annual rate of 290,000.

The investigational compound sought to combine the active ingredients from AZN's Crestor and ABT's Trilipix to treat abnormal levels of two or more lipids in the blood.

The firms said there will no financial impact to their 2010 or 2011 earnings. They did, however, at one time expect $500 million in U.S. sales each year had Certriad gained the necessary approvals.

Abbott Laboratories (ABT) is up fractionally after briefly dipping into the red and AstraZeneca plc (AZN) is holding fractional gains as well, after the companies announced they are discontinuing efforts to develop Certriad.